Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study

J Clin Psychiatry. 1998 May;59(5):229-32. doi: 10.4088/jcp.v59n0504.

Abstract

Background: The authors evaluated and compared the efficacy of 20 mg versus 40 mg of paroxetine in a randomized, double-blind, parallel-group study during a maintenance period of 28 months.

Method: Ninety-nine inpatients with recurrent, unipolar depression (DSM-IV criteria) who had at least 1 depressive episode during the 18 months preceding the index episode were openly treated with paroxetine 40 mg/day. Seventy-two subjects had a stable response (Hamilton Rating Scale for Depression score < 8) to paroxetine treatment and remained in the continuation treatment as outpatients for 4 months. At the time of recovery, 68 patients were randomly assigned to 1 of the 2 maintenance treatment groups: paroxetine 20 mg or paroxetine 40 mg daily.

Results: Sixty-seven patients completed the 28-month follow-up period. Seventeen (51.5%) of 33 patients in the 20-mg paroxetine regimen had a single recurrence compared with 8 (23.5%) of 34 subjects in the 40-mg dose regimen (chi2 = 5.56, p = .018).

Conclusion: These data suggest that a full dose of paroxetine is recommended in unipolar patients who are at high risk for recurrent depressive episodes.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age of Onset
  • Ambulatory Care
  • Depressive Disorder / drug therapy
  • Depressive Disorder / prevention & control*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Paroxetine / administration & dosage
  • Paroxetine / therapeutic use*
  • Proportional Hazards Models
  • Psychiatric Status Rating Scales
  • Recurrence
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Serotonin Uptake Inhibitors
  • Paroxetine